|
Medivation & Pfizer to terminate their collaboration to market development of Dimebon |
|
|
|
|
Top Business News
|
|
Monday, 06 February 2012 |
|
USA-based Medivation (NASDAQ: MDVN) and global drugs behemoth Pfizer (NYSE: PFE) have finally decided to discontinue the development of Dimebon also known as latrepirdine, for all indications and will terminate the ongoing open label extension study in Alzheimer's disease. |
|
Read more...
|
|
Determining the Preclinical Toxicokinetic Comparability for a Biosimilar Drug |
|
|
|
|
White Papers
|
|
Monday, 06 February 2012 |
|
Programs for biosimilar drugs usually need at least one preclinical study to support the clinical phase of development. This study must have pharmacokinetic, immunogenicity and toxicological components and provide insight into the similarities and differences (i.e., comparability) between the biosimilar and the innovator drug. |
|
Read more...
|
|
Antares Pharma Licenses A Drug Delivery Technology To Pfizer |
|
|
|
|
Top Business News
|
|
Tuesday, 10 January 2012 |
|
Antares Pharma has recently announced that it has licensed to Pfizer Inc.’s Consumer Healthcare Business Unit one of its drug delivery technologies to develop an undisclosed product on an exclusive basis for North America. The companies did not disclose specifics of the deal. |
|
Read more...
|
|
|
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
|
| Results 1 - 8 of 345 |
